Navamedic’s gross margin was 44.8 percent in Q2 2022, up from 39.3 percent in the same period last year. EBITDA was NOK 23.7 mill compared to NOK 4.3 mill in the second quarter of last year. Operating profit (EBIT) was NOK 21.9 mill compared to NOK 2.9 mill in Q2 2021.
“We are pleased to report record-high revenues and continued strengthening of our profits and cash flow in the second quarter. This was a result of strong growth across several key products, particularly the obesity drug Mysimba. We have continued to progress well along our strategic path through the strengthening of our existing portfolio by leveraging our strong market position and by adding distribution and marketing rights for attractive products. Furthermore, we have strengthened our platform through M&A with the acquisition of Impolin,” says Kathrine Gamborg Andreassen, CEO of Navamedic.
“Even though the second quarter of 2022 was a great quarter for Navamedic, we have only just started on our value creation journey. We are planning several product launches in the months to come, and we have a good pipeline of potential new distribution and marketing partnerships and acquisitions,” says Gamborg Andreassen.
